Search

Search results

87 results found

2025 HFpEF Summit: Dr. Sharp speaks on RDN in preclinical models of HFpEF

News: March 20, 2025

Dr. Sharp speaks at the 2025 HFpEF Summit, Beverly Hills, CA. A world-class summit which brings together internationally recognized experts discussing the preclinical and clinical findings in cardiometbolic disease and HF.

2025 European Journal of Heart Failure - ARTICLE: Short Report

News: May 22, 2025

Renal Denervation Improves Cardiac Function and Exercise Duration in a Miniswine Model of Heart Failure with Preserved Ejection Fraction Aims - Overactivity of the sympathetic nervous system is a common underlying mechanism in development and progression of several heart failure with preserved...

2025 JACC: Basic to Translational Science - ARTICLE

News: August 11, 2025

Hydrogen Sulfide Deficiency and Therapeutic Targeting in Cardiometabolic HFpEF Heart failure with preserved ejection fraction (HFpEF) presents significant treatment challenges. We assessed hydrogen sulfide (H 2S) bioavailability in HFpEF patients and 2 animal models: the "2-hit" L-NAME + high-fat...

Early Renal Denervation Attenuates Cardiac Dysfunction in Heart Failure With Preserved Ejection Fraction.

Publication: Journal Article

Doiron, Jake E, Zhen Li, Xiaoman Yu, Kyle B LaPenna, Heather Quiriarte, Timothy D Allerton, Kashyap Koul, et al. 2024. “Early Renal Denervation Attenuates Cardiac Dysfunction in Heart Failure With Preserved Ejection Fraction.”. Journal of the American Heart Association 13 (4): e032646.

Cardiomyocyte myofilament function in common animal models of heart failure with preserved ejection fraction.

Publication: Journal Article

Jani, Vivek P, Navid Koleini, Axel J Fenwick, Thomas E Sharp, Traci T Goodchild, Joseph A Hill, David J Lefer, Anthony Cammarato, and David A Kass. 2024. “Cardiomyocyte Myofilament Function in Common Animal Models of Heart Failure With Preserved Ejection Fraction.”. Journal of Molecular and Cellular Cardiology 197: 34-39.

Sorafenib cardiotoxicity increases mortality after myocardial infarction.

Publication: Journal Article

Duran, Jason M, Catherine A Makarewich, Danielle Trappanese, Polina Gross, Sharmeen Husain, Jonathan Dunn, Hind Lal, et al. 2014. “Sorafenib Cardiotoxicity Increases Mortality After Myocardial Infarction.”. Circulation Research 114 (11): 1700-1712.

Stem cell therapy and breast cancer treatment: review of stem cell research and potential therapeutic impact against cardiotoxicities due to breast cancer treatment.

Publication: Journal Article

Sharp, Thomas E, and Jon C George. 2014. “Stem Cell Therapy and Breast Cancer Treatment: Review of Stem Cell Research and Potential Therapeutic Impact Against Cardiotoxicities Due to Breast Cancer Treatment.”. Frontiers in Oncology 4: 299.

Thromboxane A2 blockade attenuates ethanol-induced myocardial inflammation: Sipping from the same bottle.

Publication: Journal Article

Sharp, Thomas E, and Thanh Trung Van. 2024. “Thromboxane A2 Blockade Attenuates Ethanol-Induced Myocardial Inflammation: Sipping from the Same Bottle.”. Alcohol, Clinical & Experimental Research 48 (10): 1834-36.

A Feline HFpEF Model with Pulmonary Hypertension and Compromised Pulmonary Function.

Publication: Journal Article

Wallner, Markus, Deborah M Eaton, Remus M Berretta, Giulia Borghetti, Jichuan Wu, Sandy T Baker, Eric A Feldsott, et al. 2017. “A Feline HFpEF Model With Pulmonary Hypertension and Compromised Pulmonary Function.”. Scientific Reports 7 (1): 16587.

Endothelial Cell Cystathionine γ-Lyase Expression Level Modulates Exercise Capacity, Vascular Function, and Myocardial Ischemia Reperfusion Injury.

Publication: Journal Article

Xia, Huijing, Zhen Li, Thomas E Sharp, David J Polhemus, Jean Carnal, Karl H Moles, Ya-Xiong Tao, et al. 2020. “Endothelial Cell Cystathionine γ-Lyase Expression Level Modulates Exercise Capacity, Vascular Function, and Myocardial Ischemia Reperfusion Injury.”. Journal of the American Heart Association 9 (19): e017544.